Holen Sie sich die Stockscreener-App
7.28
0.27%
-0.02
Handel nachbörslich:
7.24
-0.04
-0.55%
Schlusskurs vom Vortag:
$7.30
Offen:
$7.37
24-Stunden-Volumen:
2.67M
Relative Volume:
1.12
Marktkapitalisierung:
$1.18B
Einnahmen:
$181.41M
Nettoeinkommen (Verlust:
$-59.56M
KGV:
-17.33
EPS:
-0.42
Netto-Cashflow:
$-38.83M
1W Leistung:
+32.60%
1M Leistung:
+42.47%
6M Leistung:
+102.22%
1J Leistung:
+186.61%
1-Tages-Spanne:
$7.205
$7.42
1-Wochen-Bereich:
$6.10
$7.61
52-Wochen-Spanne:
$2.39
$7.61
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Firmenname
Xeris Biopharma Holdings Inc
Sektor
Branche
Telefon
844-445-5704
Adresse
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Vergleichen Sie XERS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
7.28 | 1.18B | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2023-08-28 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2018-07-16 | Eingeleitet | Jefferies | Buy |
| 2018-07-16 | Eingeleitet | Leerink Partners | Outperform |
| 2018-07-16 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
Dawn Halkuff sells Xeris Biopharma (XERS) shares worth $309k - Investing.com
Xeris Biopharma (XERS) Upgraded to Buy: Here's Why - Yahoo Finance
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
How liquid is Xeris Biopharma Holdings Inc. stockSpeedy Gain Trade Picks - thegnnews.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st
Wyckoff Accumulation Phase Possible in Xeris Biopharma Holdings Inc.Potential Breakout Stock List Published This Week - beatles.ru
Bollinger Bands Show Potential Breakout in Xeris Biopharma Holdings Inc.Day Trading Signals With High Precision Reviewed - beatles.ru
Xeris Biopharma Holdings Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2025 Earnings Call Transcript - Insider Monkey
XERS (Xeris Biopharma Holdings) Momentum Rank : 3 (As of Aug. 08, 2025) - GuruFocus
XERS Crosses Above Average Analyst Target - Nasdaq
Xeris Biopharma Reports Strong Q2 2025 Results - TipRanks
Beyond the Balance Sheet: What SWOT Reveals About Xeris Biopharm - GuruFocus
Xeris raises 2025 revenue guidance to $280M–$290M following 49% Q2 growth, led by Recorlev - MSN
Xeris Biopharma Holdings, Inc. SEC 10-Q Report - TradingView
Xeris Biopharma: Q2 Earnings Snapshot - The Washington Post
Xeris Biopharma Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Little Excitement Around Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Revenues - 富途牛牛
Xeris (XERS) Q2 Revenue Jumps 49% - The Motley Fool
Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Xeris Biopharma shares rise 24.23% premarket after beating Q2 revenue expectations and raising FY guidance. - AInvest
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance - BioSpace
Earnings Flash (XERS) Xeris Biopharma Posts Q2 Net Loss $0.01 a Share, vs. FactSet Est of $0.05 Loss - MarketScreener
Xeris Biopharma beats Q2 revenue expectations, raises FY guidance - MarketScreener
Institutional scanner results for Xeris Biopharma Holdings Inc.Trade Flow Monitor with Volume Tracker - Newser
Can trapped investors hope for a rebound in Xeris Biopharma Holdings Inc.Conservative Asset Allocation Risk Analysis - Newser
Xeris Biopharma Holdings Inc. stock trend outlook and recovery pathSmart Trend Analysis With Buy Point Cues - Newser
Is Xeris Biopharma Holdings Inc. building a consolidation baseBuy Alert Based on RSI and Volume - Newser
Xeris Pharmaceuticals Receives Buy Rating from Craig-Hallum, Analyst Consensus Remains Strong Buy with $6.00 Average Price Target. - AInvest
What are the technical indicators suggesting about Xeris Biopharma Holdings Inc.Sky-high return potential - Jammu Links News
Is Xeris Biopharma Holdings Inc. a good long term investmentOverwhelming financial success - Jammu Links News
Why is Xeris Biopharma Holdings Inc. stock attracting strong analyst attentionAchieve explosive financial results today - Jammu Links News
What catalysts could drive Xeris Biopharma Holdings Inc. stock higher in 2025Capitalize on fast-growing stocks today - Jammu Links News
Is Xeris Biopharma Holdings Inc. a growth stock or a value stockAchieve impressive returns with smart timing - Jammu Links News
Should I hold or sell Xeris Biopharma Holdings Inc. stock in 2025Get exclusive access to professional stock picks - Jammu Links News
Xeris Biopharma Holdings Inc. Stock Support and Resistance Levels You Should KnowEarnings Based Stock Performance Forecast - Newser
When is Xeris Biopharma Holdings Inc. stock expected to show significant growthPost Market Recommendation For 2025 - Jammu Links News
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025 - BioSpace
Why Xeris Biopharma Holdings Inc. stock attracts strong analyst attentionTrading Watchlist with Real Time Filters - Newser
What is Xeris Biopharma Holdings Inc. company’s growth strategyMarket Forecast Alerts Backed By Experts - Jammu Links News
Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xeris Biopharma Holdings Inc-Aktie (XERS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McCulloch Kevin | See Remarks |
Jun 13 '25 |
Buy |
4.38 |
25,000 |
109,475 |
1,708,585 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):